Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00403481 · ClinicalTrials.gov registry record · Phase 4
An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes
A Phase 4 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 4
- Development phase
- 192
- Enrollment target
NCT00403481 is a Phase 4 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 192 participants.
The verdict
NCT00403481, a Phase 4 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 192 participants
- Enrollment target
Study Summary
This study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients with Type II diabetes and high blood pressure. The medication being tested has been approved by the FDA for the treatment of high blood pressure.
Interventions
- DRUG olmesartan medoxomil
- DRUG Olmesartan medoxomil plus Hydrochlorothiazide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2006-11 |
| Est. Completion | 2007-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00403481
The ClinicalTrials.gov registry entry for NCT00403481 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which olmesartan medoxomil is the first listed.
NCT00403481 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00403481 about?
NCT00403481 is a clinical study titled "An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes". This study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients with Type II diabetes and high blood pressure. The medication being tested has been approved by the FDA for the treatment of high blood pressure.
What is the current status of trial NCT00403481?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 192 participants. The study started on 2006-11. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00403481?
The interventions under investigation include: olmesartan medoxomil (DRUG), Olmesartan medoxomil plus Hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT00403481?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.